Trazodone use and risk of dementia: A population-based cohort study
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In vitro and animal studies have suggested that trazodone, a licensed antidepressant, may protect against dementia. However, no studies have been conducted to assess the effect of trazodone on dementia in humans. This electronic health records study assessed the association between trazodone use and the risk of developing dementia in clinical practice. METHODS AND FINDINGS: The Health Improvement Network (THIN), an archive of anonymised medical and prescribing records from primary care practices in the United Kingdom, contains records of over 15 million patients. We assessed patients from THIN aged ≥50 years who received at least two consecutive prescriptions for an antidepressant between January 2000 and January 2017. We compared the risk of dementia among patients who were prescribed trazodone to that of patients with similar baseline characteristics prescribed other antidepressants, using a Cox regression model with 1:5 propensity score matching. Patients prescribed trazodone who met the inclusion criteria (n = 4,716; 59.2% female) were older (mean age 70.9 ± 13.1 versus 65.6 ± 11.4 years) and were more likely than those prescribed other antidepressants (n = 420,280; 59.7% female) to have cerebrovascular disease and use anxiolytic or antipsychotic drugs. After propensity score matching, 4,596 users of trazadone and 22,980 users of other antidepressants were analysed. The median time to dementia diagnosis for people prescribed trazodone was 1.8 years (interquartile range [IQR] = 0.5-5.0 years). Incidence of dementia among patients taking trazodone was higher than in matched users of other antidepressants (1.8 versus 1.1 per 100 person-years), with a hazard ratio (HR) of 1.80 (95% confidence interval [CI] 1.56-2.09; p < 0.001). However, our results do not suggest a causal association. When we restricted the control group to users of mirtazapine only in a sensitivity analysis, the findings were very similar to the results of the main analysis. The main limitation of our study is the possibility of indication bias, because people in the prodromal stage of dementia might be preferentially prescribed trazodone. Due to the observational nature of this study, we cannot rule out residual confounding. CONCLUSIONS: In this study of UK population-based electronic health records, we found no association between trazodone use and a reduced risk of dementia compared with other antidepressants. These results suggest that the clinical use of trazodone is not associated with a reduced risk of dementia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pinquart, M., & Sörensen, S. (2003) · Psychology and Aging · doi:10.1037/0882-7974.18.2.250 · Cited by 2,857
Multiple imputation of discrete and continuous data by fully conditional specification
van Buuren, S. (2007) · Statistical Methods in Medical Research · doi:10.1177/0962280206074463 · Cited by 2,827
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312889 · Cited by 1,668
Townsend, P. (1987) · Journal of Social Policy · doi:10.1017/s0047279400020341 · Cited by 1,294
Assessment and management of behavioral and psychological symptoms of dementia
Kales, H. C., Gitlin, L. N., & Lyketsos, C. G. (2015) · BMJ · doi:10.1136/bmj.h369 · Cited by 1,247
A comparison of 12 algorithms for matching on the propensity score
Austin, P. C. (2014) · Statistics in Medicine · doi:10.1002/sim.6004 · Cited by 1,085
Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease
Honig, L. S., Vellas, B., Woodward, M., Boada, M., Bullock, R., Borrie, M., Hager, K., Andreasen, N., Scarpini, E., Liu-Seifert, H., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1705971 · Cited by 1,049
Sleep and Alzheimer disease pathology--a bidirectional relationship
Ju, Y.-E. S., Lucey, B. P., & Holtzman, D. M. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2013.269 · Cited by 996
Austin, P. C. (2009) · Biometrical Journal · doi:10.1002/bimj.200810488 · Cited by 769
Preclinical research: Make mouse studies work
Perrin, S. (2014) · Nature · doi:10.1038/507423a · Cited by 668
Blak, B., Thompson, M., Dattani, H., & Bourke, A. (2011) · Journal of Innovation in Health Informatics · doi:10.14236/jhi.v19i4.820 · Cited by 630
Maguire, A., Blak, B. T., & Thompson, M. (2009) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1688 · Cited by 301
Halliday, M., Radford, H., Zents, K. A. M., Molloy, C., Moreno, J. A., Verity, N. C., Smith, E., Ortori, C. A., Barrett, D. A., Bushell, M., et al. (2017) · Brain · doi:10.1093/brain/awx074 · Cited by 293
Survival of people with clinical diagnosis of dementia in primary care: cohort study
Rait, G., Walters, K., Bottomley, C., Petersen, I., Iliffe, S., & Nazareth, I. (2010) · BMJ · doi:10.1136/bmj.c3584 · Cited by 221
Suicide-Related Events in Patients Treated with Antiepileptic Drugs
Arana, A., Wentworth, C. E., Ayuso-Mateos, J. L., & Arellano, F. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909801 · Cited by 205
Successful therapies for Alzheimer’s disease: why so many in animal models and none in humans?
Franco, R., & Cedazo-Minguez, A. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00146 · Cited by 183
Camargos, E. F., Louzada, L. L., Quintas, J. L., Naves, J. O. S., Louzada, F. M., & Nóbrega, O. T. (2014) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2013.12.174 · Cited by 170
Identifying periods of acceptable computer usage in primary care research databases
Horsfall, L., Walters, K., & Petersen, I. (2013) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3368 · Cited by 148
Trazodone and cognitive performance in Alzheimer disease
Camargos, E. F., Quintas, J. L., Louzada, L. L., Naves, J. O. S., Furioso, A. C. T., & Nóbrega, O. T. (2015) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000237 · Cited by 14
Cited by
Depression in Alzheimer’s Disease: Epidemiology, Mechanisms, and Treatment
Huang, Y.-Y., Gan, Y.-H., Yang, L., Cheng, W., & Yu, J.-T. (2024) · Biological Psychiatry · doi:10.1016/j.biopsych.2023.10.008 · Cited by 164
Depressive Symptoms in the Elderly—An Early Symptom of Dementia? A Systematic Review
Wiels, W., Baeken, C., & Engelborghs, S. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00034 · Cited by 95
Sommerlad, A., Werbeloff, N., Perera, G., Smith, T., Costello, H., Mueller, C., Kormilitzin, A., Broadbent, M., Nevado‐Holgado, A., Lovestone, S., et al. (2022) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.5625 · Cited by 14
“Firstly, a cohort study using UK general practice data reported higher incidence of dementia in 4,596 people aged over 50 years without dementia at baseline who were prescribed trazodone compared to those taking other antidepressants.(41) Secondly, a cross‐sectional observational study examining the cognitive effects…”
BackgroundResolving a paradox: antidepressants, neuroinflammation, and neurodegeneration
Rajkumar, R. P. (2024) · Exploration of Neuroprotective Therapy · doi:10.37349/ent.2024.00068 · Cited by 9
Metadata
- Authors
- Brauer, R., Lau, W. C. Y., Hayes, J. F., Man, K. K. C., Osborn, D. P. J., Howard, R., Kim, J., & Wong, I. C. K.
- Venue
- PLOS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2019-02-05
- Volume
- 16
- Issue
- 2
- Pages
- e1002728
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- OpenAlex
- W2913809295
- Cited by
- 35
- References
- 19
- FWCI
- 3.87
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.